Showing 5791-5800 of 9115 results for "".
- Women of Color May Be Disproportionately Exposed to Beauty Product Chemicalshttps://practicaldermatology.com/news/women-of-color-may-be-disproportionately-exposed-to-beauty-product-chemicals/2458087/Women with skin of color have higher levels of beauty-product related chemicals in their bodies compared to white women, according to a commentary published in the American Journal of Obstetrics and Gynecology.<
- Survey Highlights Risks of Pubic Hair Groominghttps://practicaldermatology.com/news/survey-highlights-risks-of-pubic-hair-grooming/2458086/More than one-quarter of people who groom their pubic hair sustain grooming-related injuries, according to a new article published by JAMA Dermatology. Of the 7,570 men and women who completed
- PuraCap Pharmaceuticals Introduces EpiCeram Quad Packhttps://practicaldermatology.com/news/puracap-pharmaceuticals-introduces-epiceram-quad-pack/2458088/PuraCap® Pharmaceutical is introducing the EpiCeram® Controlled Release Skin Barrier Emulsion Quad Pack, which contains four 100-gram airless pumps. EpiCeram® is a US Food and Drug Administration-approved topical prescription e
- Bonti's Novel Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://practicaldermatology.com/news/bontis-novel-serotype-e-botulinum-toxin-performs-well-in-phase-2a-study/2458094/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours
- FDA Advisory Arm Backs XELJANZ for PsAhttps://practicaldermatology.com/news/fda-advisory-arm-backs-xeljanz-for-psa/2458098/The United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommends the approval of Pfizer's XELJANZ® (tofacitinib) for the treatment of adults with active psoriatic arthritis (PsA). The Arthritis Advisory Commit
- Glenmark Pharmaceuticals Reports Positive Phase 2a Data for GBR 830 for Atopic Dermatitishttps://practicaldermatology.com/news/glenmark-pharmaceuticals-reports-positive-phase-2a-data-for-gbr-830-for-atopic-dermatitis/2458102/Glenmark Pharmaceuticals shared positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis (AD). The study evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830, relative to placebo, i
- Cutanea Life Sciences Unveils Facing Forward Mobile App for Acne Patientshttps://practicaldermatology.com/news/cutanea-life-sciences-unveils-facing-forward-new-mobile-app-for-acne-patients/2458104/Cutanea Life Sciences, Inc. introduced its Facing Forward mobile application for patients who are prescribed Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5%, a combination therapy indicated for the topical treatment of acne vulgaris. The app will be available free thro
- MKTP Surgery Shows Long-Term Benefit for Restoring Skin Pigmentation in Vitiligohttps://practicaldermatology.com/news/mktp-surgery-shows-long-term-benefit-for-restoring-skin-pigmentation-in-vitiligo/2458103/Melanocyte-keratinocyte transplantation (MKTP) provides long-term benefits for restoring skin pigmentation caused by vitiligo, report researchers from Henry Ford Hospital in Detroit. “MKTP works and it lasts a long time,” says Iltefat Hamzavi, M.D., a Henry Ford dermatologist
- Valeant Launches Siliq Injection for Psoriasishttps://practicaldermatology.com/news/valeant-launches-siliq-injection-for-psoriasis/2458107/Valeant Pharmaceuticals International, Inc. launched Siliq (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking place in New York from July 27-30, 2017. Siliq, a
- Simulation Techniques Help Medical Students Empathize with Melanoma Patientshttps://practicaldermatology.com/news/simulation-techniques-help-medical-students-empathize-with-melanoma-patients/2458110/Simulation techniques can allow doctors to experience what it feels like to be a melanoma patient. The study, which is led by Queen’s University in Belfast collaboration with researchers from the University of Huddersfield and University College Dublin, appears in the